InsidersTradesSigma
HLB파나진 Stock: price and management transactions · South Korea · DART (FSS)
Follow the HLB파나진 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, HLB파나진 has recorded 49 insider filings. Market capitalisation: €66bn. The latest transaction was reported on 30 June 2026 (Other). Among the most active insiders: HLB. Every trade is openly available.
49
Insider Decl.
0
Thresholds
€5m
25 ops.
Buy Volume
€4m
4 ops.
Sell Volume
15Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,550 of 26,182 companies
31.8
score / 100
Value21
Quality43
FCF yld-5.0%
Earn yld-6.1%
EV/EBITDA·
ROE·
Gross mgn60%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 June 2026
Declarations49 total
25 of 49 declarations
About HLB파나진
HLB파나진 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of innovative treatments and therapeutic solutions.